Grace Therapeutics is a rare and orphan disease drug company.  Grace develops novel formulation and delivery technologies for approved molecules to address critical unmet medical needs for new and existing indications.

The company's strategy is to create differentiated products with superior value proposition, strong IP and orphan designation.  The preferred regulatory pathway is 505(b)(2) which is de-risked, capital efficient, and enables expedited product approval. 

Grace's pipeline consists of three distinct assets that are in advanced clinical development for Postherpetic Neuralgia, Subarachnoid Hemorrhage, and Ataxia Telangiectasia, with two additional assets for Trigeminal Neuralgia and Aortic Aneurysm that are advancing toward the clinic.  Grace intends to pursue multiple commercialization options for these assets to maximize value, including establishing its own salesforce in niche markets. 

The company founders have a successful track record in developing products from concept to approval and commercialization with multi-billion-dollar revenues over the product life-cycle.